Blog
Regeneron Seeks to Bifurcate or Stay Amgen’s Antitrust Claims in Aflibercept Patent Litigation
On December 11, 2025, Regeneron filed a Memorandum in Support of Its Motion to Bifurcate and Stay Amgen’s Antitrust Claims in the ongoing aflibercept patent litigation in the U.S. District Court for the Northern District of West Virginia….
By: Goodwin